CAS: 13679-74-8; 2-Acetyl-5-Methylthiophene

相似化合物

1344955-52-7 4565-29-1 88-15-3

上下游产品

CAS号554-14-3 2-甲基噻吩 | CAS号108-24-7 乙酸酐 | CAS号75-36-5 乙酰氯 | CAS号4282-31-9 噻吩-2,5-二羧酸 | CAS号1918-79-2 5-甲基-2-噻吩甲酸 | CAS号40323-88-4 2-乙基-5-甲基噻吩 | CAS号326-72-7 1,3-Butanedione... | CAS号4066-41-5 5-乙酰基噻吩-2-甲酸 | CAS号31555-59-6 5-甲基噻吩-2-酰氯 | CAS号13792-96-6 2-[3,5-bis(5-me... | CAS号36901-17-4 1-(4-bromo-5-me... | CAS号70624-30-5 2-(5-甲基噻吩-2-基)乙酸

在 Sodium Hydroxide体系中,化学反应生成2-乙酰-5-甲基噻吩
参考文献:一系列4-和5-取代的2-([[ 3 H]乙酰基)噻吩的破坏动力学
标题:一系列4-和5-取代的2-([[ 3 H]乙酰基)噻吩的破坏动力学
摘要:制备了一系列的4-和5-取代的2-([[ 3 H]乙酰基)噻吩,并在25.0oc下研究了氢氧化物催化的降解动力学.二阶降解速率常数与在相应的间位和对位取代的苯乙酮中观测到的平行,但随着反应常数ρ较高(1.61),反应范围比对苯乙酮所观测到的要宽得多.
Doi:10.1039/p29850000557

专利信息

专利号:US-8513241-B2
优先权日:2008-03-28
标题 :3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
发明人：CERVI GIOVANNI; D ANELLO MATTEO; PAPEO GIANLUCA MARIANO ENRICO; SALOM BARBARA
权利人:CERVI GIOVANNI; D ANELLO MATTEO; PAPEO GIANLUCA MARIANO ENRICO; SALOM BARBARA; NERVIANO MEDICAL SCIENCES SRL
摘要:Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

专利号:US-7361671-B2
优先权日:2001-11-15
标 题 :Substituted heteroarylalkanoic acids
发明人：VAN ZANDT MICHAEL C; GERACI LEO
权利人:INST PHARMACEUTICAL DISCOVERY
摘要:Disclosed are substituted heteroarylalkanoic acids acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.